Headline
अगली पीढ़ी की नैनोमेडिसिन से कैंसर के प्रमुख कारक निष्क्रिय हो सकते हैं (Next-generation nanomedicine can inactivate major cancer factors)
Extracted Data Points:
- Scientists from Pune have developed a gene silencing strategy that can effectively control tumors in breast cancer
- The research was conducted by Agharkar Research Institute (ARI), an autonomous institute under the Department of Science and Technology (DST), Government of India
- The research presents a novel biodegradable nanocarrier platform for targeted gene therapy in breast cancer
- The study was recently published in Advanced Healthcare Materials
- The system is based on biodegradable mesoporous silica nanoparticles known for high loading capacity and tunable surface chemistry
- The nanocarrier enables efficient delivery of small interfering RNA (siRNA) molecules
- Researchers functionalized the nanocarrier with protamine biopolymer and MUC-1-specific aptamer
- The targeting strategy exploits over-expression of MUC-1 receptors on breast cancer cells
- The approach features dual-gene-silencing against two important anti-apoptotic genes: MCL-1 and Survivin
- These genes are known to promote tumor survival and treatment resistance
- The glutathione-responsive design enables controlled release of therapeutic payload in the tumor microenvironment
- Biological evaluation in MCF-7 breast cancer model demonstrated strong gene knockdown
- Results showed increased apoptosis and significant inhibition of tumor growth
- In vivo studies in severe combined immunodeficiency (SCID) mice showed effective accumulation at tumor sites
- The nanocarrier demonstrated minimal systemic toxicity as evidenced by favorable histological outcomes
- The research provides a solid framework for next-generation RNAi-based cancer treatments
- The work was conducted by scientists from the Nanobiosciences group at Agharkar Research Institute, Pune
- Publication link: https://advanced.onlinelibrary.wiley.com/doi/abs/10.1002/adhm.202505296?af=R